The AZT Therapeutics Program
The therapeutic effectiveness of Tocotrienols (T3s) is dependent on how much is bioavailable systemically. By improving the bioavailability of T3s using the TransT3 and TPD platforms, an improvement in the efficacy of T3s in therapeutic indications should be possible.
VTL has chosen to target two therapeutic indications with great unmet needs, Non-Alcoholic Fatty Liver Disease (NAFLD) and pancreatic cancer, where T3s have shown some promising activity in animal models and (in the case of NAFLD) also clinical studies.
VTL currently has four prescription drug candidates with T3 as the active pharmaceutical ingredient in development:
ABN 35 111 082 485